| Ibritumomab Tiuxetan studied in …STUDIED_INderived28 of 28show fewer |
|---|
| → studied in | NCT00168727Phase 4 · completed Zevalin® Followed by Rituxan® Maintenance in Previously Treated Low Grade Non-Hodgkin's Lymphoma · 28 trials list this drug (0 active) | — | — | Lymphoma,Non-Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01811368Phase 2 · unknown Zevalin Before Stem Cell Transplant in Treating Patients With Non-Hodgkin Lymphoma · 28 trials list this drug (0 active) | — | — | Non-Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00493467Phase 2 · completed Zevalin (Ibritumomab Tiuxetan) for Early Stage Indolent Lymphomas · 28 trials list this drug (0 active) | — | — | Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00290511Phase 2 · completed Rituximab, Fludarabine, Mitoxantrone, Dexamethasone (R-FND) Plus Zevalin for High-Risk Follicular Lymphoma · 28 trials list this drug (0 active) | — | — | Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00322218Phase 3 · terminated Study Comparing Zevalin Regimen With no Further Treatment in Patients With Diffuse Large B-cell Lymphoma. · 28 trials list this drug (0 active) | — | — | Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01510184Phase 3 · terminated Study of Zevalin Versus Observation in Participants at Least 60 Years Old With Newly Diagnosed Diffuse Large B-cell Lymphoma in Positron Emission Tomography (PET)-Negative Complete Remission After Rituximab-Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) or R-CHOP-like Therapy · 28 trials list this drug (0 active) | — | — | Diffuse Large B-Cell Lymphoma,Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01662102Phase 3 · terminated Rituximab or Zevalin - Efficacy Trial of Therapeutic Alternatives (RoZetta) · 28 trials list this drug (0 active) | — | — | Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00591630Phase 2 · completed Zevalin/BEAM/Rituximab vs BEAM/Rituximab With or Without Rituximab in Autologous Stem Cell Transplantation · 28 trials list this drug (0 active) | — | — | Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00491491Phase 3 · completed Zevalin-beam for Aggressive Lymphoma · 28 trials list this drug (0 active) | — | — | Non-Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00662948Phase 2 · completed ZAR2007: R-CHOP in Folicular Lymphoma Patients no Treated Previously. Consolidation With 90Y Ibritumomab Tiuxetan (Zevalin®) Versus Maintenance Treatment With Rituximab (MabThera®) · 28 trials list this drug (0 active) | — | — | Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00372905Phase 1/Phase 2 · terminated Phase I/II Trial of VELCADE Plus Zevalin in Patients With Relapsed or Refractory Follicular Lymphoma · 28 trials list this drug (0 active) | — | — | Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00392691Phase 1 · completed Melphalan, Yttrium Y 90 Ibritumomab Tiuxetan, and Rituximab Followed by Autologous Stem Cell Transplant in Treating Older Patients With Non-Hodgkin's Lymphoma That Has Relapsed or Not Responded to Previous Treatment · 28 trials list this drug (0 active) | — | — | Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00644371Phase 2 · completed Allogenic Stem Cell Transplantation (SCT) With Non-myeloablative Conditioning in Patients With Relapse Non-Hodgkin's Lymphoma (NHL) · 28 trials list this drug (0 active) | — | — | Non-Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00607854Phase 2 · completed Safety of Ibritumomab Tiuxetan (Zevalin®) in Combination With a Fludarabine-based Reduced Intensity Conditioning (RIC) Regimen (ZEVALLO 2007) · 28 trials list this drug (0 active) | — | — | Diffuse Large B-Cell Lymphoma,Mantle Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00453102Phase 2 · completed Yttrium Y 90 Ibritumomab Tiuxetan and Rituximab in Treating Patients With Previously Untreated Marginal Zone Lymphoma · 28 trials list this drug (0 active) | — | — | Marginal Zone Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00319332Phase 3 · withdrawn A Comparative Study Of Iodine I 131 Tositumomab Therapeutic Regimen Versus Ibritumomab Tiuxetan Therapeutic Regimen · 28 trials list this drug (0 active) | — | — | Lymphoma,Non-Hodgkin Lymphoma,Follicular Lymphoma+1 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00220285Phase 2 · completed Study for Evaluation of Efficacy and Safety of SH L 749 to Indolent B-cell Non-Hodgkin's Lymphoma · 28 trials list this drug (0 active) | — | — | B-Cell Malignant Neoplasm,Lymphoma,Non-Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00119730Phase 2 · completed Chemotherapy Followed by Zevalin for Relapsed Mantle Cell Lymphoma · 28 trials list this drug (0 active) | — | — | Mantle Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00387023NA · completed Radioimmunotherapy With 90Y Zevalin for Orbital Lymphoma · 28 trials list this drug (0 active) | — | — | Lymphoma,Non-Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00493454Phase 2 · terminated Ibritumomab Tiuxetan for Treatment of Non-Follicular CD20+ Indolent Lymphomas · 28 trials list this drug (0 active) | — | — | Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00521560Phase 2 · completed A Study of Zevalin and Simultaneous Application of BEAM High-dose Chemotherapy Followed by Autologous Stem Cell Transplantation in Refractory and Relapsed Aggressive Non-Hodgkin Lymphomas · 28 trials list this drug (0 active) | — | — | Non-Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00193440Phase 2 · completed Rituximab and Chemotherapy Followed by Ibritumomab Tiuxetan as Treatment for Low Grade Follicular Non-Hodgkin's Lymphoma · 28 trials list this drug (0 active) | — | — | Non-Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01157988Phase 2 · completed 90Y-ibritumomab Tiuxetan Consolidation After 6th R-CHOP Chemotherapy in Patients With Bulky Diffuse Large B Cell Lymphoma · 28 trials list this drug (0 active) | — | — | Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00354822Phase 2 · terminated Fludarabine,Cyclophosphamide and Rituximab Followed by Zevalin for Non-Follicular Indolent Lymphomas. · 28 trials list this drug (0 active) | — | — | Non-Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00859001Phase 2 · completed Study to Evaluate the Efficacy and Safety of Subsequent Treatment With the Zevalin (Ibritumomab Tiuxetan) Study in Patients With Follicular Grade I-II Lymphoma After 4 Cycles of Fludarabine-Mitoxantrone-Rituximab (FMR) Therapy · 28 trials list this drug (0 active) | — | — | Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00850512Phase 2 · completed Study to Evaluate the Efficacy and Safety of Subsequent Treatment With the Zevalin (Ibritumomab Tiuxetan) in Elderly (More Than 60 Years) Patients With Diffuse Large B Cell Lymphoma After 4 Cycles of CHOP21-Rituximab (CHOP21-R) Therapy · 28 trials list this drug (0 active) | — | — | Diffuse Large B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00185393Phase 3 · completed Treatment With [90]Y-Ibritumomab Tiuxetan Versus no Treatment in Patients With Follicular Non Hodgkin Lymphoma (Stage III or IV) Having Achieved a Partial or Complete Remission After First Line Chemotherapy · 28 trials list this drug (0 active) | — | — | Non-Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00057343Phase 3 · terminated Safety and Efficacy of Zevalin in the Treatment of Non-Hodgkin's Lymphoma · 28 trials list this drug (0 active) | — | — | Non-Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |